[1] HVSEMANN Y,GEIGL J B,SCHUBERT F,et al.Systemic spread is an early step in breast cancer[J].Cancer Cell,2008,13(1):58-68.
[2] CRISTOFANILLI M,BUDD G T,ELLIS M J,et al.Circulating tumor cells,disease progression,and survival in metastatic breast cancer[J].New Engl J Med,2004,351(8):781-791.
[3] USIAKOVA Z,MIKULOVA V,PINTEROVA D,et al.Circulating tumor cells in patients with breast cancer:monitoring chemotherapy success[J].In Vivo,2014,28(4):605-614.
[4] PACHMANN K,CAMARA O,KAVALLARIS A,et al.Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse[J].J ClinOncol,2008,26(8):1208-1215.
[5] SMERAGE J B,BARLOW W E,HORTOBAGYI G N,et al.Circulating tumor cells and response to chemotherapy in metastatic breast cancer:SWOG S0500[J].J Clin Oncol,2014,32(31):3483-3489.
[6] GRADILONE A,NASO G,RAIMONDI C,et al.Circulating tumor cells (CTCs) in metastatic breast cancer (MBC):prognosis,drug resistance and phenotypic characterization[J].Ann Oncol,2010,22(1):86-92.
[7] AKTAS B,MVLLER V,TEWES M,et al.Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients[J].Gynecol Oncol,2011,122(2):356-360.
[8] NADAL R,GONZALEZ L,ALBANELL J,et al.Biomarkers characterization of circulating tumor cells in breast cancer patients[J].Breast Cancer Res,2012,14(3):R71.
[9] HARRIS J R,LIPPMAN M E,MORROW M,et al.乳腺病学[M].4版.济南:山东科学技术出版社,2006:946
[10] ROMOND E H,PEREZ E A,BRYANT J,et al.Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer[J].N Engl J Med,2005,353(16):1673-1684.
[11] SMITH I,PROCTER M,GELBER R D,et al.2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer:a randomised controlled trial[J].Lancet,2007,369(9555):29-36.
[12] PEATRIN M,BESSI S,GALARDI F,et al.Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients[J].Breast Cancer Res Treat,2009,118(3):523-530.
[13] HAYASHI N,NAKAMURA S,TOKUDA Y,et al.Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer[J].Int J ClinOncol,2012,17(2):96-104.
[14] APOSTOLAKI S,PERRAKI M,PALLIS A,et al.Circulating HER2 mRNA-positive cells in the peripheral blood of patients with stage I and II breast cancer after the administration of adjuvant chemotherapy:evaluation of their clinical relevance[J].Ann Oncol,2007,18(5):851-858.
[15] MENG S,TRIPATHY D,SHETE S,et al.HER-2 gene amplification can be acquired as breast cancer progresses[J].Proc Natl Acad Sci USA,2004,101(25):9393-9398.
[16] LIU Y,LIU Q,WANG T,et al.Circulating tumor cells in HER2-positive metastatic breast cancer patients:a valuable prognostic and predictive biomarker[J].BMC Cancer,2013,13:202.
[17] MUNZONE E,NOLÉ F,GOLDHIRSCH A,et al.Changes of HER2 status in circulating tumor cells compared with the primary tumor during treatment for advanced breast cancer[J].Clin Breast Cancer,2010,10(5):392-397. |
